Breast Cancer: Major Risk Factors and Recent Developments in Treatment

被引：116

作者：

Majeed, Wafa ^{[1
]}

Aslam, Bilal ^{[1
]}

Javed, Ijaz ^{[1
]}

Khaliq, Tanweer ^{[1
]}

Muhammad, Faqir ^{[1
]}

Ali, Asghar ^{[1
]}

Raza, Ahmad ^{[1
]}

机构：

[1] Univ Agr Faisalabad, Dept Physiol & Pharmacol, Faisalabad, Pakistan

来源：

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2014年 / 15卷 / 08期

关键词：

Cancer; breast cancer; leptin; BRCA1; BRCA2; antibodies; enzyme inhibitors; POSTMENOPAUSAL WOMEN; TAMOXIFEN; ANASTROZOLE; FULVESTRANT; METAANALYSIS; DOXORUBICIN; INHIBITION; STRATEGIES; LETROZOLE; APOPTOSIS;

D O I：

10.7314/APJCP.2014.15.8.3353

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is the most common in women worldwide, with some 5-10% of all cases due to inherited mutations of BRCA1 and BRCA2 genes. Obesity, hormone therapy and use of alcohol are possible causes and over-expression of leptin in adipose tissue may also play a role. Normally surgery, radiation therapy and chemotherapy allow a good prognosis where screening measures are in place. New hope in treatment measures include adjuvant therapy, neoadjuvant therapy, and introduction of mono-clonal antibodies and enzyme inhibitors.

引用

页码：3353 / 3358

页数：6

共 34 条

[1] Fulvestrant for advanced breast cancer: A meta-analysis
Al-Mubarak, Mustafa
Sacher, Adrian G.
Ocana, Alberto
Vera-Badillo, Francisco
Seruga, Bostjan
Amir, Eitan
[J]. CANCER TREATMENT REVIEWS, 2013, 39 (07) : 753 - 758
[2] A signature of immune function genes associated with recurrence-free survival in breast cancer patients
Ascierto, Maria Libera
Kmieciak, Maciej
Idowu, Michael O.
Manjili, Rose
Zhao, Yingdong
Grimes, Margaret
Dumur, Catherine
Wang, Ena
Ramakrishnan, Viswanathan
Wang, Xiang-Yang
Bear, Harry D.
Marincola, Francesco M.
Manjili, Masoud H.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (03) : 871 - 880
[3] Hereditary breast cancer: ever more pieces to the polygenic puzzle
Bogdanova, Natalia
Helbig, Sonja
Doerk, Thilo
[J]. HEREDITARY CANCER IN CLINICAL PRACTICE, 2013, 11
[4] Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions
Bot, Adrian
Marincola, Francesco
Smith, Kent A.
[J]. EXPERT REVIEW OF VACCINES, 2013, 12 (10) : 1219 - 1234
[5] Brandao RD, 2013, BREAST CANCER RES, V15, P1
[6] Brittany W, 2013, EFFICACY SAFETY STUD
[7] Adjuvant Hormonal Therapy for Early-Stage Breast Cancer
Burstein, Harold J.
Griggs, Jennifer J.
[J]. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 19 (03) : 639 - +
[8] Pertuzumab: new hope for patients with HER2-positive breast cancer
Capelan, M.
Pugliano, L.
De Azambuja, E.
Bozovic, I.
Saini, K. S.
Sotiriou, C.
Loi, S.
Piccart-Gebhart, M. J.
[J]. ANNALS OF ONCOLOGY, 2013, 24 (02) : 273 - 282
[9] Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
Chia, Y. H.
Ellis, M. J.
Ma, C. X.
[J]. BRITISH JOURNAL OF CANCER, 2010, 103 (06) : 759 - 764
[10] Expert perspectives on biosimilar monoclonal antibodies in breast cancer
Cortes, J.
Curigliano, G.
Dieras, V.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 144 (02) : 233 - 239

← 1 2 3 4 →